Skip to main content
Premium Trial:

Request an Annual Quote

Dutch VC Shop Invests $2.7M in Jurilab to Help Drive Metabolic Syndrome Research

NEW YORK (GenomeWeb News) — DSM Venturing has invested €2 million ($2.7 million) in Finnish diagnostics company Jurilab, DSM said today.
 
Jurilab specializes in disease markers and pathways, drug targets, and diagnostic content for metabolic syndrome. DSM, a financing branch of the Dutch company Royal DSM, said it believes that Jurilab’s access to the “relatively homogenous” East Finland founder population and its databank make its approach “faster, more informative, and more cost-effective than many traditional screening approaches."
 
Metabolic syndrome is sometimes used as an umbrella term to cover obesity, type 2 diabetes, dyslipidemia, and hypertension, DSM said. The market for diagnostics and personalized approaches to these diseases will continue to grow as populations age and become more health conscious, DSM said.
 
DSM last year put $2.6 million into its nutrigenomics programs through an investment in molecular diagnostics company Integragen.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.